IL118171A - Stable liquid composition containing urate oxidase and its preparation - Google Patents

Stable liquid composition containing urate oxidase and its preparation

Info

Publication number
IL118171A
IL118171A IL11817196A IL11817196A IL118171A IL 118171 A IL118171 A IL 118171A IL 11817196 A IL11817196 A IL 11817196A IL 11817196 A IL11817196 A IL 11817196A IL 118171 A IL118171 A IL 118171A
Authority
IL
Israel
Prior art keywords
urate oxidase
preparation
composition containing
liquid composition
stable liquid
Prior art date
Application number
IL11817196A
Other languages
English (en)
Other versions
IL118171A0 (en
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IL118171A0 publication Critical patent/IL118171A0/xx
Publication of IL118171A publication Critical patent/IL118171A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
IL11817196A 1995-05-11 1996-05-07 Stable liquid composition containing urate oxidase and its preparation IL118171A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9505606A FR2733914B1 (fr) 1995-05-11 1995-05-11 Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US08/644,163 US5811096A (en) 1995-05-11 1996-05-10 Stable liquid composition containing urate oxidase and lyophilized composition for its preparation

Publications (2)

Publication Number Publication Date
IL118171A0 IL118171A0 (en) 1996-09-12
IL118171A true IL118171A (en) 2000-08-31

Family

ID=26231954

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11817196A IL118171A (en) 1995-05-11 1996-05-07 Stable liquid composition containing urate oxidase and its preparation

Country Status (24)

Country Link
US (1) US5811096A (zh)
EP (1) EP0742013B1 (zh)
JP (1) JP2950775B2 (zh)
CN (1) CN1090972C (zh)
AT (1) ATE183925T1 (zh)
AU (1) AU710288B2 (zh)
BR (1) BR1100337A (zh)
CA (1) CA2175971C (zh)
CZ (1) CZ290799B6 (zh)
DE (1) DE69604009T2 (zh)
DK (1) DK0742013T3 (zh)
EA (1) EA000024B1 (zh)
ES (1) ES2137635T3 (zh)
FR (1) FR2733914B1 (zh)
GR (1) GR3031896T3 (zh)
HU (1) HU225147B1 (zh)
IL (1) IL118171A (zh)
NO (1) NO315261B1 (zh)
NZ (1) NZ286554A (zh)
PL (1) PL184135B1 (zh)
SG (1) SG42355A1 (zh)
SI (1) SI0742013T1 (zh)
TW (1) TW420614B (zh)
ZA (1) ZA963683B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
DK2158923T3 (da) 1998-08-06 2013-03-25 Mountain View Pharmaceuticals Peg-uratoxidase-konjugater og anvendelse deraf
FR2782455B3 (fr) * 1998-08-20 2000-09-15 Sanofi Sa Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine
US8765124B2 (en) * 2003-02-28 2014-07-01 Chugai Seiyaku Kabushiki Kaisha Stabilized preparation containing protein
DK1610822T4 (en) 2003-04-02 2019-01-14 Ares Trading Sa Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant
WO2004112826A1 (en) * 2003-06-20 2004-12-29 Ares Trading Sa Freeze-dried fsh / lh formulations
PT3321359T (pt) 2005-04-11 2021-03-11 Horizon Pharma Rheumatology Llc Formas variantes de urato-oxidase e a sua utilização
CN101194016B (zh) 2005-04-11 2012-09-05 萨文特医药公司 尿酸氧化酶的变体形式及其用途
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
CN1864744B (zh) * 2005-05-18 2010-09-29 杭州北斗生物技术有限公司 含有尿酸氧化酶的药用制剂
EP1883425A1 (en) * 2005-05-23 2008-02-06 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
HU230758B1 (hu) 2006-04-12 2018-03-28 Crealta Pharmaceuticals LLC 100% Fehérjék tisztítása kationos felületaktív anyaggal
CA2766309A1 (en) 2009-06-25 2010-12-29 Savient Pharmaceuticals, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN105412942B (zh) * 2015-12-23 2019-02-26 沈阳三生制药有限责任公司 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
WO2017180594A1 (en) * 2016-04-13 2017-10-19 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928137A (en) * 1971-10-20 1975-12-23 Mallinckrodt Inc Reagent formulation for uric acid assay
US3997470A (en) * 1971-10-20 1976-12-14 Mallinckrodt, Inc. Surfactant containing reagent formulations for assaying biological specimens and methods of preparing same
JPS51104807A (en) * 1975-03-12 1976-09-17 Hitachi Ltd Teepurekoodano ootoribaasuseigyokairo
JPS5417027A (en) * 1977-07-07 1979-02-08 Canon Inc Image forming system
DE3126759A1 (de) * 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
JPS60224499A (ja) * 1984-04-23 1985-11-08 Toyobo Co Ltd 安定なウリカ−ゼ製剤
DE3743405A1 (de) * 1987-05-14 1988-11-24 Boehringer Mannheim Gmbh Verfahren zur bestimmung von fructosamin
JPH0243471A (ja) * 1988-08-03 1990-02-14 Iwataro Moriyama 立体駐車装置

Also Published As

Publication number Publication date
DE69604009T2 (de) 2000-04-06
EA199600024A3 (ru) 1997-03-31
JPH0925242A (ja) 1997-01-28
FR2733914B1 (fr) 1997-08-01
CZ290799B6 (cs) 2002-10-16
EP0742013A1 (fr) 1996-11-13
MX9601756A (es) 1997-07-31
CN1147961A (zh) 1997-04-23
HUP9601241A2 (en) 1997-04-28
HU225147B1 (en) 2006-07-28
AU710288B2 (en) 1999-09-16
IL118171A0 (en) 1996-09-12
DK0742013T3 (da) 2000-03-06
ATE183925T1 (de) 1999-09-15
NO315261B1 (no) 2003-08-11
NZ286554A (en) 1998-09-24
EA000024B1 (ru) 1997-12-30
DE69604009D1 (de) 1999-10-07
JP2950775B2 (ja) 1999-09-20
ES2137635T3 (es) 1999-12-16
HU9601241D0 (en) 1996-07-29
NO961915L (no) 1996-11-12
TW420614B (en) 2001-02-01
BR1100337A (pt) 2000-07-25
EA199600024A2 (ru) 1996-12-30
US5811096A (en) 1998-09-22
CA2175971C (en) 2003-12-30
SG42355A1 (en) 1997-08-15
PL314147A1 (en) 1996-11-12
CA2175971A1 (en) 1996-11-12
SI0742013T1 (en) 1999-12-31
GR3031896T3 (en) 2000-02-29
PL184135B1 (pl) 2002-09-30
ZA963683B (en) 1997-11-10
CN1090972C (zh) 2002-09-18
EP0742013B1 (fr) 1999-09-01
FR2733914A1 (fr) 1996-11-15
AU5213996A (en) 1996-11-21
HUP9601241A3 (en) 2000-06-28
CZ135096A3 (en) 1996-12-11
NO961915D0 (no) 1996-05-10

Similar Documents

Publication Publication Date Title
IL118171A (en) Stable liquid composition containing urate oxidase and its preparation
ATE193830T1 (de) Zubereitungen enthaltend leflunomide
LU92613I2 (fr) Saxagliptin et ses dérivés pharmaceutiquement acceptables (ONGLYZA)
AU7549696A (en) Bioadhesive pharmaceutical composition for the controlled release of active principles
AU681452B2 (en) Pernasal composition and pernasal preparation containing thesame
AU1560692A (en) Capsule
AU647933B2 (en) Megestrol acetate formulation
ITMI911580A1 (it) Preparazioni oftalmiche a rilascio protratto
CA2294448A1 (en) Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins
CA2125643A1 (en) Pharmaceutical composition having analgesic activity
CA2103725A1 (en) Composition for use in transdermal administration
HK1036413A1 (en) Solution comprising prostaglandins and benzyl alcohol.
CA2220103A1 (en) Composition comprising amoxycillin and clavulanic acid
Lambert-Zechovsky et al. Usefulness of time-kill curves to select an optimal beta-lactam-aminoglycoside combination against Pseudomonas aeruginosa. In vitro study of 40 Pseudomonas aeruginosa isolated in pediatric intensive care units.
AU2458492A (en) Medicaments for treating gastrointestinal disorders

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired